Ronny Dvir's questions to Vir Biotechnology Inc (VIR) leadership • Q1 2025
Question
Ronny Dvir, on behalf of Eric Joseph, asked how a recent clinical update on bulevirtide impacts VIR's strategic thinking around the potential for finite versus long-term chronic treatment for Hepatitis Delta Virus (HDV).
Answer
Mark Eisner (Executive) contrasted VIR's approach by emphasizing the high rates of complete viral suppression (64% at week 36) seen in the SOLSTICE study, compared to bulevirtide's 12% at week 48. He noted that the competitor's finite treatment data involves a higher, off-label dose. He reiterated that VIR is aiming for a potent, chronic viral suppressive regimen, supported by deep viral suppression and significant declines in hepatitis B surface antigen.